Supportive Care in Cancer

, Volume 22, Issue 1, pp 279–287 | Cite as

Cognitive impairment in gynecologic cancers: a systematic review of current approaches to diagnosis and treatment

  • Christine D. Craig
  • Bradley J. Monk
  • John H. Farley
  • Dana M. Chase
Review Article

Abstract

Purpose

To review the etiology and assessment of chemotherapy-related cognitive impairment (CRCI). To explore current treatment and prevention strategies for CRCI and propose future research goals in the field of gynecologic oncology.

Methods

Computerized searches in PubMed of cognitive impairment in cancer between 2000 and 2012 were conducted. The inclusion criteria were randomized control trials evaluating treatment of CRCI and search terms 'cognitive function, cognitive impairment, cognitive decline, chemobrain, chemofog, and cancer'.

Results

To date, numerous modalities have been utilized for assessing CRCI in patients undergoing therapy. It has been proposed to move towards web-based assessment modalities as a possible standard. Few studies have aimed to elucidate possible treatment and prevention options for CRCI; even less in the field of gynecologic oncology. Only seven of these studies were subjected to randomized control trials. Only one of these studies looked at treatment in patients with gynecologic cancers.

Conclusions

The etiology of CRCI is multi-factorial. Following from this, there is no consensus on the best way to assess CRCI although objective measures are more reliable. One must extrapolate data from the non-gynecologic cancer literature, even venturing to non-cancer literature, to explore the treatment and prevention of CRCI. The methods found in these areas of research have not yet been applied to CRCI in gynecologic oncology.

Keywords

Gynecologic cancer Chemotherapy-related cognitive impairment Treatment and prevention 

Notes

Conflict of interest

There are no financial conflicts of interest to disclose.

References

  1. 1.
    Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB (2008) Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice Cognitive Workshop. Ann Oncol 19(4):623–629CrossRefPubMedGoogle Scholar
  2. 2.
    Boykoff N, Moieni M, Subramanian SK (2009) Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response. J Cancer Surviv 3(4):223–232CrossRefPubMedGoogle Scholar
  3. 3.
  4. 4.
    Ahles TA, Saykin AJ (2007) Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 7(3):192–201CrossRefPubMedGoogle Scholar
  5. 5.
    Kurita GP, Sjogren P, Ekholm O et al (2011) Prevalence and predictors of cognitive dysfunction in opioid-treated patients with cancer: a multinational study. J Clin Oncol 29(10):1297–1303CrossRefPubMedGoogle Scholar
  6. 6.
    Stavraka C, Ford A, Ghaem-Maghami S et al (2012) A study of symptoms described by ovarian cancer survivors. Gynecol Oncol 125(1):59–64CrossRefPubMedGoogle Scholar
  7. 7.
    Reid-Arndt SA (2009) Breast cancer and "chemobrain": the consequences of cognitive difficulties following chemotherapy and the potential for recovery. Mo Med 106(2):127–131PubMedGoogle Scholar
  8. 8.
    Burton CL, Strauss E, Hultsch DF, Hunter MA (2006) Cognitive functioning and everyday problem solving in older adults. Clin Neuropsychol 20(3):432–452CrossRefPubMedGoogle Scholar
  9. 9.
    Reiriz AB, Reolon GK, Preissler T, et al (2006) Cancer chemotherapy and cognitive function in rodent models: memory impairment induced by cyclophosphamide in mice. Clin Cancer Res;12(16):5000; author reply 5000–1Google Scholar
  10. 10.
    Dietrich J, Han R, Yang Y, Mayer-Proschel M, Noble M (2006) CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 5(7):22CrossRefPubMedGoogle Scholar
  11. 11.
    Han R, Yang YM, Dietrich J, Luebke A, Mayer-Proschel M, Noble M (2008) Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol 7(4):12CrossRefPubMedGoogle Scholar
  12. 12.
    Briones TL, Woods J (2011) Chemotherapy-induced cognitive impairment is associated with decreases in cell proliferation and histone modifications. BMC Neurosci 12:124CrossRefPubMedGoogle Scholar
  13. 13.
    Gangloff A, Hsueh WA, Kesner AL et al (2005) Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel. J Nucl Med 46(11):1866–1871PubMedGoogle Scholar
  14. 14.
    Mayerhofer K, Bodner K, Saletu B et al (2001) Paclitaxel–carboplatin chemotherapy does not cause encephalopathy in patients with ovarian cancer: a prospective EEG mapping study in 28 patients. Anticancer Res 21(1B):803–808PubMedGoogle Scholar
  15. 15.
    Kreukels BP, Schagen SB, Ridderinkhof KR et al (2006) Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: An electrophysiologic study. Clin Breast Cancer 7(1):67–78CrossRefPubMedGoogle Scholar
  16. 16.
    Cheung YT, Chui WK, Chan A (2012) Neuro-cognitive impairment in breast cancer patients: pharmacological considerations. Crit Rev Oncol Hematol 83(1):99–111CrossRefPubMedGoogle Scholar
  17. 17.
    Schagen SB, Hamburger HL, Muller MJ, Boogerd W, van Dam FS (2001) Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J Neurooncol 51(2):159–165CrossRefPubMedGoogle Scholar
  18. 18.
    Madhyastha S, Somayaji SN, Rao MS, Nalini K, Bairy KL (2002) Hippocampal brain amines in methotrexate-induced learning and memory deficit. Can J Physiol Pharmacol 80(11):1076–1084CrossRefPubMedGoogle Scholar
  19. 19.
    Walker CH, Drew BA, Antoon JW, Kalueff AV, Beckman BS (2012) Neurocognitive effects of chemotherapy and endocrine therapies in the treatment of breast cancer: recent perspectives. Cancer Invest 30(2):135–148CrossRefPubMedGoogle Scholar
  20. 20.
    Aluise CD, Sultana R, Tangpong J et al (2010) Chemo brain (chemo fog) as a potential side effect of doxorubicin administration: role of cytokine-induced, oxidative/nitrosative stress in cognitive dysfunction. Adv Exp Med Biol 678:147–156PubMedGoogle Scholar
  21. 21.
    Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D (2002) Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 87(1):21–27CrossRefPubMedGoogle Scholar
  22. 22.
    Pusztai L, Mendoza TR, Reuben JM et al (2004) Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 25(3):94–102CrossRefPubMedGoogle Scholar
  23. 23.
    Penson RT, Kronish K, Duan Z et al (2000) Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 10(1):33–41CrossRefPubMedGoogle Scholar
  24. 24.
    Lutgendorf SK, Weinrib AZ, Penedo F et al (2008) Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol 26(29):4820–4827CrossRefPubMedGoogle Scholar
  25. 25.
    Szelenyi J (2001) Cytokines and the central nervous system. Brain Res Bull 54(4):329–338CrossRefPubMedGoogle Scholar
  26. 26.
    Tangpong J, Sompol P, Vore M et al (2008) Tumor necrosis factor alpha-mediated nitric oxide production enhances manganese superoxide dismutase nitration and mitochondrial dysfunction in primary neurons: an insight into the role of glial cells. Neuroscience 151(2):622–629CrossRefPubMedGoogle Scholar
  27. 27.
    Tangpong J, Cole MP, Sultana R et al (2006) Adriamycin-induced, TNF-alpha mediated central nervous system toxicity. Neurobiol Dis 23(1):127–139CrossRefPubMedGoogle Scholar
  28. 28.
    Joshi G, Sultana R, Tangpong J et al (2005) Free radical mediated oxidative stress and toxic side effects in brain induced by the anti cancer drug adriamycin: insight into chemobrain. Free Radic Res 39(11):1147–1154CrossRefPubMedGoogle Scholar
  29. 29.
    Konat GW, Kraszpulski M, James I, Zhang HT, Abraham J (2008) Cognitive dysfunction induced by chronic administration of common cancer chemotherapeutics in rats. Metab Brain Dis 23(3):325–333CrossRefPubMedGoogle Scholar
  30. 30.
    Seigers R, Timmermans J, van der Horn HJ et al (2010) Methotrexate reduces hippocampal blood vessel density and activates microglia in rats but does not elevate central cytokine release. Behav Brain Res 207(2):265–272CrossRefPubMedGoogle Scholar
  31. 31.
    Correa DD, Zhou Q, Thaler HT, Maziarz M, Hurley K, Hensley ML (2010) Cognitive functions in long-term survivors of ovarian cancer. Gynecol Oncol 119(2):366–369CrossRefPubMedGoogle Scholar
  32. 32.
    Meyers CA (2000) Neurocognitive dysfunction in cancer patients. Oncology (Williston Park). ;14(1):75–9; discussion 79, 81–2, 85Google Scholar
  33. 33.
    Meyers CA, Wefel JS (2003) The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol 21(19):3557–3558CrossRefPubMedGoogle Scholar
  34. 34.
    Suri D, Vaidya VA (2012) Glucocorticoid regulation of brain-derived neurotrophic factor: relevance to hippocampal structural and functional plasticity. NeuroscienceGoogle Scholar
  35. 35.
    Aleman A, Torres-Aleman I (2009) Circulating insulin-like growth factor I and cognitive function: neuromodulation throughout the lifespan. Prog Neurobiol 89(3):256–265CrossRefPubMedGoogle Scholar
  36. 36.
    Parker WH, Jacoby V, Shoupe D, Rocca W (2009) Effect of bilateral oophorectomy on women's long-term health. Womens Health (Lond Engl) 5(5):565–576CrossRefPubMedGoogle Scholar
  37. 37.
    Vodermaier A (2009) Breast cancer treatment and cognitive function: the current state of evidence, underlying mechanisms and potential treatments. Womens Health (Lond Engl) 5(5):503–516CrossRefPubMedGoogle Scholar
  38. 38.
    Loibl S, Lintermans A, Dieudonne AS, Neven P (2011) Management of menopausal symptoms in breast cancer patients. Maturitas 68(2):148–154CrossRefPubMedGoogle Scholar
  39. 39.
    Dutta V (2011) Chemotherapy, neurotoxicity, and cognitive changes in breast cancer. J Cancer Res Ther 7(3):264–269CrossRefPubMedGoogle Scholar
  40. 40.
    Hess LM, Chambers SK, Hatch K et al (2010) Pilot study of the prospective identification of changes in cognitive function during chemotherapy treatment for advanced ovarian cancer. J Support Oncol 8(6):252–258CrossRefPubMedGoogle Scholar
  41. 41.
    Hermelink K, Kuchenhoff H, Untch M et al (2010) Two different sides of 'chemobrain': determinants and nondeterminants of self-perceived cognitive dysfunction in a prospective, randomized, multicenter study. Psychooncology 19(12):1321–1328CrossRefPubMedGoogle Scholar
  42. 42.
    Hensley ML, Correa DD, Thaler H et al (2006) Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning. Gynecol Oncol 102(2):270–277CrossRefPubMedGoogle Scholar
  43. 43.
    Deprez S, Amant F, Smeets A et al (2012) Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol 30(3):274–281CrossRefPubMedGoogle Scholar
  44. 44.
    Silverman DH, Dy CJ, Castellon SA et al (2007) Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy. Breast Cancer Res Treat 103(3):303–311CrossRefPubMedGoogle Scholar
  45. 45.
    Lower EE, Fleishman S, Cooper A et al (2009) Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manage 38(5):650–662CrossRefPubMedGoogle Scholar
  46. 46.
    Mar Fan HG, Clemons M, Xu W et al (2008) A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer 16(6):577–583CrossRefPubMedGoogle Scholar
  47. 47.
    Kohli S, Fisher SG, Tra Y et al (2009) The effect of modafinil on cognitive function in breast cancer survivors. Cancer 115(12):2605–2616CrossRefPubMedGoogle Scholar
  48. 48.
    Lundorff LE, Jonsson BH, Sjogren P (2009) Modafinil for attentional and psychomotor dysfunction in advanced cancer: a double-blind, randomised, cross-over trial. Palliat Med 23(8):731–738CrossRefPubMedGoogle Scholar
  49. 49.
    O'Shaughnessy JA (2002) Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy. Clin Breast Cancer 3(Suppl 3):S116–S120CrossRefPubMedGoogle Scholar
  50. 50.
    Fan HG, Park A, Xu W et al (2009) The influence of erythropoietin on cognitive function in women following chemotherapy for breast cancer. Psychooncology 18(2):156–161CrossRefPubMedGoogle Scholar
  51. 51.
    Jatoi A, Kahanic SP, Frytak S et al (2005) Donepezil and vitamin E for preventing cognitive dysfunction in small cell lung cancer patients: preliminary results and suggestions for future study designs. Support Care Cancer 13(1):66–69CrossRefPubMedGoogle Scholar
  52. 52.
    Chan KK, Yao TJ, Jones B et al (2011) The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: a double-blind placebo-controlled randomized trial with immunological monitoring. Ann Oncol 22(10):2241–2249CrossRefPubMedGoogle Scholar
  53. 53.
    Attia A, Rapp SR, Case LD et al (2012) Phase II study of Ginkgo biloba in irradiated brain tumor patients: effect on cognitive function, quality of life, and mood. J Neurooncol 109(2):357–363CrossRefPubMedGoogle Scholar
  54. 54.
    Heishman SJ, Kleykamp BA, Singleton EG (2010) Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology (Berl) 210(4):453–469CrossRefPubMedGoogle Scholar
  55. 55.
    Raffa RB (2011) Cancer 'survivor-care': I. The alpha7 nAChR as potential target for chemotherapy-related cognitive impairment. J Clin Pharm Ther 36(4):437–445CrossRefPubMedGoogle Scholar
  56. 56.
    Speca M, Carlson LE, Goodey E, Angen M (2000) A randomized, wait-list controlled clinical trial: the effect of a mindfulness meditation-based stress reduction program on mood and symptoms of stress in cancer outpatients. Psychosom Med 62(5):613–622PubMedGoogle Scholar
  57. 57.
    Biegler KA, Chaoul MA, Cohen L (2009) Cancer, cognitive impairment, and meditation. Acta Oncol 48(1):18–26CrossRefPubMedGoogle Scholar
  58. 58.
    Oh B, Butow PN, Mullan BA et al (2012) Effect of medical qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a randomized controlled trial. Support Care Cancer 20(6):1235–1242CrossRefPubMedGoogle Scholar
  59. 59.
    Cohen K (1999) The way of qigong. 1st trade paperback ed. New York: Ballantine Books; 427Google Scholar
  60. 60.
    Galantino ML, Greene L, Daniels L, Dooley B, Muscatello L, O'Donnell L (2012) Longitudinal impact of yoga on chemotherapy-related cognitive impairment and quality of life in women with early stage breast cancer: a case series. Explore (NY) 8(2):127–135CrossRefPubMedGoogle Scholar
  61. 61.
    Fardell JE, Vardy J, Shah JD, Johnston IN (2012) Cognitive impairments caused by oxaliplatin and 5-fluorouracil chemotherapy are ameliorated by physical activity. Psychopharmacology (Berl) 220(1):183–193CrossRefPubMedGoogle Scholar
  62. 62.
    Ferguson RJ, McDonald BC, Rocque MA et al (2012) Development of CBT for chemotherapy-related cognitive change: Results of a waitlist control trial. Psychooncology 21(2):176–186CrossRefPubMedGoogle Scholar
  63. 63.
    Joly F, Rigal O, Noal S, Giffard B (2011) Cognitive dysfunction and cancer: which consequences in terms of disease management? Psychooncology 20(12):1251–1258CrossRefPubMedGoogle Scholar
  64. 64.
    Mori T, Rezai-Zadeh K, Koyama N et al (2012) Tannic acid is a natural beta-secretase inhibitor that prevents cognitive impairment and mitigates Alzheimer-like pathology in transgenic mice. J Biol Chem 287(9):6912–6927CrossRefPubMedGoogle Scholar
  65. 65.
    Sattler C, Toro P, Schonknecht P, Schroder J (2012) Cognitive activity, education and socioeconomic status as preventive factors for mild cognitive impairment and Alzheimer's disease. Psychiatry Res 196(1):90–95CrossRefPubMedGoogle Scholar
  66. 66.
    Fardell JE, Vardy J, Johnston IN, Winocur G (2011) Chemotherapy and cognitive impairment: treatment options. Clin Pharmacol Ther 90(3):366–376CrossRefPubMedGoogle Scholar
  67. 67.
    Grimmett C, Bridgewater J, Steptoe A, Wardle J (2011) Lifestyle and quality of life in colorectal cancer survivors. Qual Life Res 20(8):1237–1245CrossRefPubMedGoogle Scholar
  68. 68.
    Scapagnini G, Vasto S, Abraham NG, Caruso C, Zella D, Fabio G (2011) Modulation of Nrf2/ARE pathway by food polyphenols: a nutritional neuroprotective strategy for cognitive and neurodegenerative disorders. Mol Neurobiol 44(2):192–201CrossRefPubMedGoogle Scholar
  69. 69.
    Hajjar I, Hart M, Chen YL et al (2012) Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Arch Intern Med 172(5):442–444CrossRefPubMedGoogle Scholar
  70. 70.
    Brinton LA, Sakoda LC, Frederiksen K et al (2007) Relationships of uterine and ovarian tumors to pre-existing chronic conditions. Gynecol Oncol 107(3):487–494CrossRefPubMedGoogle Scholar
  71. 71.
    Wefel JS, Vardy J, Ahles T, Schagen SB (2011) International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12(7):703–708CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Christine D. Craig
    • 1
  • Bradley J. Monk
    • 1
  • John H. Farley
    • 1
  • Dana M. Chase
    • 1
  1. 1.St. Joseph’s Hospital and Medical Center, Division of Gynecologic OncologyPhoenixUSA

Personalised recommendations